Comparative Pharmacology
Head-to-head clinical analysis: TRAVATAN versus YUVEZZI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVATAN versus YUVEZZI.
TRAVATAN vs YUVEZZI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective FP prostanoid receptor agonist; increases uveoscleral outflow of aqueous humor by relaxing the ciliary muscle and remodeling the extracellular matrix in the ciliary body.
YUVEZZI is not a recognized drug. No mechanism available.
One drop of 0.004% ophthalmic solution in the affected eye(s) once daily in the evening.
150 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 45 minutes for travoprost acid (active metabolite). Clinical context: due to rapid systemic clearance, ocular hypotensive effect persists for 24 hours from corneal tissue binding.
Terminal elimination half-life of 8–12 hours; permits twice-daily dosing in most indications
Renal (primarily as metabolites): ~70%; Fecal: ~25%; Unchanged drug in urine: <1%
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog